Sponsored by:

Harrison.ai wins U.S. FDA clearance for acute infarct triage

Radiology AI company Harrison.ai has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its acute infarct triage software on noncontrast CT brain scans.

The software is intended to ensure that suspected ischemic stroke patients are prioritized for follow-up, including advanced imaging, according to the company.

Acute infarct triage targets not just large vessel occlusions but infarcts in the anterior cerebral artery, middle cerebral artery, posterior cerebral artery, cerebellum, basilar artery, and watershed border zones. Harrison.ai said the software has achieved 89.2% sensitivity on thin slices and 85.7% on thick slices, with greater than 80% sensitivity and specificity across multiple operating points for both thin and thick slice series.

This is the company's ninth 510(k) submission and second of three Breakthrough Device Designations. With it, both hemorrhagic and ischemic stroke are now covered in one integration, according to the firm.

Page 1 of 681
Next Page